Prolia Binding Assays
BioOutsource has a wide-ranging expertize in the design, optimization, qualification and implementation of innovative binding assays suitable for the assessment of a range of monoclonal antibody therapeutics. This provides a robust platform for the development of novel solutions to the quantification, assessment, and comparison of Prolia (Denosumab) in binding assays. We have developed binding assays to characterize the Fab binding for RANKL (Receptor activator of nuclear factor kappa-B ligand). The performance of binding assays to the Fc region can be developed using our standard Fc-binding platform approach.
Interaction and affinity methodologies are fundamental to the evaluation of monoclonal antibodies as therapeutic products. BioOutsource can utilize a broad range of techniques to assess the association and dissociation of denosumab with RANKL target protein ligand. These methods have been developed using a variety of platforms including ELISA, Electrochemiluminescence (MSD) or Surface Plasmon Resonance and can be achieved with a variety of different reporting mechanisms including affinity, on and off rates, coupled with relative binding using a totality of data evaluation approach to provide you with complete, industry-leading comparability reports to understand all aspects of the performance of your denosumab molecule.
Learn more about our RANKL binding Assays.